Exclusive Summary

• Seize the golden 'patent cliff' window of the multi-billion-dollar global blockbuster Apixaban to rapidly secure early-mover advantage in generic cardiovascular distribution.
• Heavily endorsed as a first-line agent by the WHO EML and premier guidelines, the 2.5mg strength uniquely caters to the essential safety requirements of vulnerable demographics—such as the elderly, low-weight patients, and post-orthopedic surgical cases.
• Backed by China's scalable, high-quality pharmaceutical manufacturing, offering disruptive pricing to guarantee lucrative local distributor margins and unmatched tender competitiveness.